prikaz prve stranice dokumenta Dual antiplatelet therapy in patients with aspirin resistance following coronary artery bypass grafting: study protocol for a randomized controlled trial
  Preuzmi
PDF 356.4 KB
Znanstveni rad - Izvorni znanstveni rad
Dual antiplatelet therapy in patients with aspirin resistance following coronary artery bypass grafting: study protocol for a randomized controlled trial
Trials, 13 (2012), 148; https://doi.org/10.1186/1745-6215-13-148
Gašparović, Hrvoje; Petričević, Mate; Kopjar, Tomislav; Đurić, Željko; Svetina, Lucija; Biočina, Bojan

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Gašparović, H., Petričević, M., Kopjar, T., Đurić, Ž., Svetina, L. i Biočina, B. (2012). Dual antiplatelet therapy in patients with aspirin resistance following coronary artery bypass grafting: study protocol for a randomized controlled trial . Trials, 13. (148). doi: 10.1186/1745-6215-13-148

Gašparović, Hrvoje, et al. "Dual antiplatelet therapy in patients with aspirin resistance following coronary artery bypass grafting: study protocol for a randomized controlled trial ." Trials, vol. 13, br. 148, 2012. https://doi.org/10.1186/1745-6215-13-148

Gašparović, Hrvoje, Mate Petričević, Tomislav Kopjar, Željko Đurić, Lucija Svetina i Bojan Biočina. "Dual antiplatelet therapy in patients with aspirin resistance following coronary artery bypass grafting: study protocol for a randomized controlled trial ." Trials 13, br. 148 (2012). https://doi.org/10.1186/1745-6215-13-148

Gašparović, H., et al. (2012) 'Dual antiplatelet therapy in patients with aspirin resistance following coronary artery bypass grafting: study protocol for a randomized controlled trial ', Trials, 13(148). doi: 10.1186/1745-6215-13-148

Gašparović H, Petričević M, Kopjar T, Đurić Ž, Svetina L, Biočina B. Dual antiplatelet therapy in patients with aspirin resistance following coronary artery bypass grafting: study protocol for a randomized controlled trial . Trials [Internet]. 25.08.2012. [pristupljeno 16.05.2024.];13(148). doi: 10.1186/1745-6215-13-148

H. Gašparović, M. Petričević, T. Kopjar, Ž. Đurić, L. Svetina i B. Biočina, "Dual antiplatelet therapy in patients with aspirin resistance following coronary artery bypass grafting: study protocol for a randomized controlled trial ", Trials, vol. 13, br. 148, Kolovoz 2012. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:611554. [Citirano: 16.05.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:611554
Podaci o radu
Naslov (engleski)Dual antiplatelet therapy in patients with aspirin resistance following coronary artery bypass grafting: study protocol for a randomized controlled trial
Naslov (hrvatski)NCT01159639
AutorHrvoje Gašparović
AutorMate Petričević
AutorTomislav Kopjar
AutorŽeljko Đurić
AutorLucija Svetina
AutorBojan Biočina
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
BACKGROUND: Coronary artery disease remains the dominant cause of mortality in developed countries. While platelets have been recognized to play a pivotal role in atherothrombosis, the ideal antiplatelet regime after coronary artery surgery remains elusive. The evolution of CABG has presently moved beyond technical improvements to involve modulation of pharmacologic management designed to improve patient outcomes. The aim of this trial will be to test the hypothesis that the addition of clopidogrel to patients with documented postoperative aspirin resistance will reduce the incidence of major cardiovascular events. ----- METHODS: Patients scheduled for isolated coronary artery surgery will be eligible for the study. Patients in whom postoperative multiple electrode aggregometry documents aspirin resistance will be randomized into two groups. The control group will receive 300 mg of aspirin. The dual antiplatelet group will receive 75 mg of clopidogrel in addition to 300 mg of aspirin. Patients will be followed for 6 months. Major adverse cardiac and cerebrovascular events (death from any cause, myocardial infarction, stroke, hospitalization due to cardiovascular pathology) as well as bleeding events will be recorded. ----- DISCUSSION: This will be the first trial that will specifically address the issue of dual antiplatelet therapy in patients undergoing coronary artery surgery who have been found to be aspirin resistant. In the event that the addition of clopidogrel proves to be beneficial in this subset of surgical patients, this study could significantly impact their future antiplatelet management. This randomized controlled trial has been registered at the ClinicalTrials.gov website (Identifier NCT01159639).
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaTrials
Brojčani podacivol. 13, br. 148
p-ISSN1745-6215
DOIhttps://doi.org/10.1186/1745-6215-13-148
URN:NBNurn:nbn:hr:105:611554
Datum objave publikacije2012-08-25
URL dokumentahttps://doi.org/10.1186/1745-6215-13-148
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-27 19:43:15